GRIN2D and schizophrenia: In summary, we have profiled the antibody repertoire in brain tissue and serum and identified elevated levels of antibodies against the GluN2D subunit of the NMDAR complex in a subgroup of subjects with schizophrenia and young adult patients with a wider spectrum of early stage psychiatric disorder using an affinity proteomics approach.